{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T06:30:38Z","timestamp":1768285838568,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2013,9,4]],"date-time":"2013-09-04T00:00:00Z","timestamp":1378252800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2013,9,4]],"date-time":"2013-09-04T00:00:00Z","timestamp":1378252800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Background<\/jats:title>\n                        <jats:p>Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are systemic inflammatory disorders that include granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), Churg-Strauss syndrome and renal limited vasculitis (RLV). Extracellular high-mobility group box 1 (HMGB1) acts as an alarmin and has been shown to be a biomarker of disease activity as well as an autoantigen in systemic lupus erythematosus (SLE) and, possibly, in AAV. This study aims to assess antibodies against HMGB1 and HMGB1 levels as biomarkers for AAV disease activity and predictors of relapsing disease.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>AAV patients with active disease and healthy controls (HC) were evaluated for anti-HMGB1 antibodies while serum HMGB1 levels were measured longitudinally in AAV patients at presentation, during remission, prior to and at relapses.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>HMGB1 levels were similar between AAV patients at presentation (<jats:italic>n<\/jats:italic> = 52) and HC (<jats:italic>n<\/jats:italic> = 35) (2.64 \u00b1 1.80 ng\/ml vs. 2.39 \u00b1 1.09 ng\/ml; <jats:italic>P<\/jats:italic> = 0.422) and no difference regarding HMGB1 levels could be found among AAV disease subsets (GPA: 2.66 \u00b1 1.83 ng\/ml vs. MPA: 3.11 \u00b1 1.91 ng\/ml vs. RLV: 1.92 \u00b1 1.48 ng\/ml; <jats:italic>P<\/jats:italic> = 0.369). AAV patients with renal involvement had lower HMGB1 levels than patients without renal involvement at presentation (2.35 \u00b1 1.48 ng\/ml vs. 3.52 \u00b1 2.41 ng\/ml; <jats:italic>P<\/jats:italic> = 0.042). A negative correlation was observed between HMGB1 levels and 24-hour proteinuria (\u03c1 = -0.361, <jats:italic>P<\/jats:italic> = 0.028). Forty-nine AAV patients were evaluated for HMGB1 levels during follow-up and no differences were observed between relapsing and nonrelapsing patients (<jats:italic>P<\/jats:italic> = 0.350). No significant increase in HMGB1 levels was observed prior to a relapse compared with the remission period and changes in HMGB1 levels were not associated with an increased risk for relapse in AAV. Positivity for anti-HMGB1 antibodies was low in patients with active AAV (three out of 24 patients).<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusions<\/jats:title>\n                        <jats:p>Serum HMGB1 levels at presentation are not increased and are lower in patients with renal involvement. Relapses are not preceded or accompanied by significant rises in HMGB1 levels and changes in HMGB1 levels are not related to ensuing relapses. Anti-HMGB1 antibodies are present in only a few patients in AAV. In contrast to SLE, HMGB1 is not a useful biomarker in AAV.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/ar4284","type":"journal-article","created":{"date-parts":[[2013,9,4]],"date-time":"2013-09-04T12:17:46Z","timestamp":1378297066000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Is serum HMGB1 a biomarker in ANCA-associated vasculitis?"],"prefix":"10.1186","volume":"15","author":[{"given":"Alexandre Wagner Silva","family":"de Souza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Westra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Bijzet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter C","family":"Limburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Coen A","family":"Stegeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Bijl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cees GM","family":"Kallenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,9,4]]},"reference":[{"key":"4397_CR1","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/art.1780370206","volume":"37","author":"JC Jennette","year":"1994","unstructured":"Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, Hagen EC, Hoffman GS, Hunder GG, Kallenberg CG: Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994, 37: 187-192. 10.1002\/art.1780370206.","journal-title":"Arthritis Rheum"},{"key":"4397_CR2","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/S0140-6736(06)69114-9","volume":"368","author":"X Bosch","year":"2006","unstructured":"Bosch X, Guilabert A, Font J: Antineutrophil cytoplasmic antibodies. Lancet. 2006, 368: 404-418. 10.1016\/S0140-6736(06)69114-9.","journal-title":"Lancet"},{"key":"4397_CR3","doi-asserted-by":"publisher","first-page":"621","DOI":"10.7326\/0003-4819-143-9-200511010-00005","volume":"143","author":"SL Hogan","year":"2005","unstructured":"Hogan SL, Falk RJ, Chin H, Cai J, Jennette CE, Jennette JC, Nachman PH: Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med. 2005, 143: 621-631. 10.7326\/0003-4819-143-9-200511010-00005.","journal-title":"Ann Intern Med"},{"key":"4397_CR4","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa041884","volume":"352","author":"Wegener's Granulomatosis Etanercept Trial (WGET) Research Group","year":"2005","unstructured":"Wegener's Granulomatosis Etanercept Trial (WGET) Research Group: Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med. 2005, 352: 351-361.","journal-title":"N Engl J Med"},{"key":"4397_CR5","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1093\/rheumatology\/kei272","volume":"45","author":"JS Sanders","year":"2006","unstructured":"Sanders JS, Huitma MG, Kallenberg CG, Stegeman CA: Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment. Rheumatology (Oxford). 2006, 45: 724-729. 10.1093\/rheumatology\/kei272.","journal-title":"Rheumatology (Oxford)"},{"key":"4397_CR6","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/art.33361","volume":"64","author":"M Walsh","year":"2012","unstructured":"Walsh M, Flossmann O, Berden A, Westman K, Hoglund P, Stegeman C, Jayne D, European Vasculitis Study Group: Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2012, 64: 542-548. 10.1002\/art.33361.","journal-title":"Arthritis Rheum"},{"key":"4397_CR7","doi-asserted-by":"publisher","first-page":"240","DOI":"10.2215\/CJN.05610611","volume":"7","author":"JG McGregor","year":"2012","unstructured":"McGregor JG, Hogan SL, Hu Y, Jennette CE, Falk RJ, Nachman PH: Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease. Clin J Am Soc Nephrol. 2012, 7: 240-247. 10.2215\/CJN.05610611.","journal-title":"Clin J Am Soc Nephrol"},{"key":"4397_CR8","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1093\/rheumatology\/kem022","volume":"46","author":"ER Popa","year":"2007","unstructured":"Popa ER, Stegeman CA, Abdulahad WH, van der Meer B, Arends J, Manson WM, Bos NA, Kallenberg CG, Tervaert JW: Staphylococcal toxic-shock-syndrome-toxin-1 as a risk factor for disease relapse in Wegener's granulomatosis. Rheumatology (Oxford). 2007, 46: 1029-1033. 10.1093\/rheumatology\/kem022.","journal-title":"Rheumatology (Oxford)"},{"key":"4397_CR9","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/rheumatology\/ker280","volume":"51","author":"G Tomasson","year":"2012","unstructured":"Tomasson G, Grayson PC, Mahr AD, Lavalley M, Merkel PA: Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis - a meta-analysis. Rheumatology (Oxford). 2012, 51: 100-109. 10.1093\/rheumatology\/ker280.","journal-title":"Rheumatology (Oxford)"},{"key":"4397_CR10","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nrrheum.2011.222","volume":"8","author":"HE Harris","year":"2012","unstructured":"Harris HE, Andersson U, Pisetsky DS: HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol. 2012, 8: 195-202. 10.1038\/nrrheum.2011.222.","journal-title":"Nat Rev Rheumatol"},{"key":"4397_CR11","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.autrev.2012.03.007","volume":"11","author":"AW de Souza","year":"2012","unstructured":"de Souza AW, Westra J, Limburg PC, Bijl M, Kallenberg CG: HMGB1 in vascular diseases: its role in vascular inflammation and atherosclerosis. Autoimmun Rev. 2012, 11: 909-917. 10.1016\/j.autrev.2012.03.007.","journal-title":"Autoimmun Rev"},{"key":"4397_CR12","doi-asserted-by":"publisher","first-page":"R184","DOI":"10.1186\/ar4015","volume":"14","author":"DA Abdulahad","year":"2012","unstructured":"Abdulahad DA, Westra J, Bijzet J, Dolff S, van Dijk MC, Limburg PC, Kallenberg CG, Bijl M: Urine levels of HMGB1 in systemic lupus erythematosus patients with and without renal manifestations. Arthritis Res Ther. 2012, 14: R184-10.1186\/ar4015.","journal-title":"Arthritis Res Ther"},{"key":"4397_CR13","doi-asserted-by":"publisher","first-page":"R71","DOI":"10.1186\/ar3332","volume":"13","author":"DA Abdulahad","year":"2011","unstructured":"Abdulahad DA, Westra J, Bijzet J, Limburg PC, Kallenberg CG, Bijl M: High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus. Arthritis Res Ther. 2011, 13: R71-10.1186\/ar3332.","journal-title":"Arthritis Res Ther"},{"key":"4397_CR14","doi-asserted-by":"publisher","first-page":"R36","DOI":"10.1186\/ar3747","volume":"14","author":"A Zickert","year":"2012","unstructured":"Zickert A, Palmblad K, Sundelin B, Chavan S, Tracey KJ, Bruchfeld A, Gunnarsson I: Renal expression and serum levels of high mobility group box 1 protein in lupus nephritis. Arthritis Res Ther. 2012, 14: R36-10.1186\/ar3747.","journal-title":"Arthritis Res Ther"},{"key":"4397_CR15","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1136\/ard.2009.119172","volume":"69","author":"D Wibisono","year":"2010","unstructured":"Wibisono D, Csernok E, Lamprecht P, Holle JU, Gross WL, Moosig F: Serum HMGB1 levels are increased in active Wegener's granulomatosis and differentiate between active forms of ANCA-associated vasculitis. Ann Rheum Dis. 2010, 69: 1888-1889. 10.1136\/ard.2009.119172.","journal-title":"Ann Rheum Dis"},{"key":"4397_CR16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2119\/molmed.2010.00132","volume":"17","author":"A Bruchfeld","year":"2011","unstructured":"Bruchfeld A, Wendt M, Bratt J, Qureshi AR, Chavan S, Tracey KJ, Palmblad K, Gunnarsson I: High-mobility group box-1 protein (HMGB1) is increased in antineutrophilic cytoplasmatic antibody (ANCA)-associated vasculitis with renal manifestations. Mol Med. 2011, 17: 29-35.","journal-title":"Mol Med"},{"key":"4397_CR17","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1136\/ard.2010.146456","volume":"70","author":"F Henes","year":"2011","unstructured":"Henes F, Chen Y, Bley T, Fabel M, Both M, Herrmann K, Csernok E, Gross W, Moosig F: Correlation of serum level of high mobility group box 1 with the burden of granulomatous inflammation in granulomatosis with polyangiitis (Wegener's). Ann Rheum Dis. 2011, 70: 1926-1929. 10.1136\/ard.2010.146456.","journal-title":"Ann Rheum Dis"},{"key":"4397_CR18","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1136\/ard.2006.054593","volume":"66","author":"R Watts","year":"2007","unstructured":"Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, Mahr A, Segelmark M, Cohen-Tervaert JW, Scott D: Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007, 66: 222-227.","journal-title":"Ann Rheum Dis"},{"key":"4397_CR19","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1136\/ard.2008.101279","volume":"68","author":"C Mukhtyar","year":"2009","unstructured":"Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, Flossmann O, Hall C, Hollywood J, Jayne D, Jones R, Lanyon P, Muir A, Scott D, Young L, Luqmani RA: Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis. 2009, 68: 1827-1832. 10.1136\/ard.2008.101279.","journal-title":"Ann Rheum Dis"},{"key":"4397_CR20","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3109\/s10165-009-0151-7","volume":"19","author":"A Hayashi","year":"2009","unstructured":"Hayashi A, Nagafuchi H, Ito I, Hirota K, Yoshida M, Ozaki S: Lupus antibodies to the HMGB1 chromosomal protein: epitope mapping and association with disease activity. Mod Rheumatol. 2009, 19: 283-292. 10.1007\/s10165-009-0151-7.","journal-title":"Mod Rheumatol"},{"key":"4397_CR21","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s00134-011-2192-6","volume":"37","author":"S Barnay-Verdier","year":"2011","unstructured":"Barnay-Verdier S, Fattoum L, Borde C, Kaveri S, Gibot S, Marechal V: Emergence of autoantibodies to HMGB1 is associated with survival in patients with septic shock. Intensive Care Med. 2011, 37: 957-962. 10.1007\/s00134-011-2192-6.","journal-title":"Intensive Care Med"},{"key":"4397_CR22","doi-asserted-by":"publisher","first-page":"c194","DOI":"10.1159\/000118942","volume":"108","author":"F Sato","year":"2008","unstructured":"Sato F, Maruyama S, Hayashi H, Sakamoto I, Yamada S, Uchimura T, Morita Y, Ito Y, Yuzawa Y, Maruyama I, Matsuo S: High mobility group box chromosomal protein 1 in patients with renal diseases. Nephron Clin Pract. 2008, 108: c194-c201. 10.1159\/000118942.","journal-title":"Nephron Clin Pract"},{"key":"4397_CR23","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1002\/lt.21573","volume":"14","author":"M Ilmakunnas","year":"2008","unstructured":"Ilmakunnas M, Tukiainen EM, Rouhiainen A, Rauvala H, Arola J, Nordin A, Makisalo H, Hockerstedt K, Isoniemi H: High mobility group box 1 protein as a marker of hepatocellular injury in human liver transplantation. Liver Transpl. 2008, 14: 1517-1525. 10.1002\/lt.21573.","journal-title":"Liver Transpl"},{"key":"4397_CR24","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1189\/jlb.0306196","volume":"81","author":"V Urbonaviciute","year":"2007","unstructured":"Urbonaviciute V, Furnrohr BG, Weber C, Haslbeck M, Wilhelm S, Herrmann M, Voll RE: Factors masking HMGB1 in human serum and plasma. J Leukoc Biol. 2007, 81: 67-74.","journal-title":"J Leukoc Biol"},{"key":"4397_CR25","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.3899\/jrheum.110091","volume":"38","author":"R Pullerits","year":"2011","unstructured":"Pullerits R, Urbonaviciute V, Voll RE, Forsblad-D'Elia H, Carlsten H: Serum levels of HMGB1 in postmenopausal patients with rheumatoid arthritis: associations with proinflammatory cytokines, acute-phase reactants, and clinical disease characteristics. J Rheumatol. 2011, 38: 1523-1525.","journal-title":"J Rheumatol"},{"key":"4397_CR26","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1189\/jlb.1212662","volume":"93","author":"H Yang","year":"2013","unstructured":"Yang H, Antoine DJ, Andersson U, Tracey KJ: The many faces of HMGB1: molecular structure-functional activity in inflammation, apoptosis, and chemotaxis. J Leukoc Biol. 2013, 93: 865-873. 10.1189\/jlb.1212662.","journal-title":"J Leukoc Biol"},{"key":"4397_CR27","volume-title":"Antioxid Redox Signal","author":"DS Pisetsky","year":"2013","unstructured":"Pisetsky DS: The translocation of nuclear molecules during inflammation and cell death. Antioxid Redox Signal. 2013,"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar4284.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/ar4284\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar4284.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T10:04:55Z","timestamp":1728381895000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/ar4284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,4]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2013,10]]}},"alternative-id":["4397"],"URL":"https:\/\/doi.org\/10.1186\/ar4284","relation":{},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,4]]},"assertion":[{"value":"4 December 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2013","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"R104"}}